← Patent Expiry Watch
October 8, 2026 · Patent expires February 1, 2029
Jardiance (Empagliflozin): The 2029 Generic Opportunity Window
A critical future target for generic manufacturers, Jardiance (empagliflozin) is a blockbuster SGLT2 inhibitor jointly developed by Boehringer Ingelheim and Eli Lilly. The projected generic opportunity window opens in early 2029, following the expiration of key patents and pediatric extensions. Active unresolved Hatch-Waxman litigation disputes are excluded from this timeline.
What we do
We track expirations like this continuously
This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.